Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin – From Bench to Bedside

Thomas Efferth

Abstract

Secondary metabolites from plants serve as defense against herbivores, microbes, viruses, or competing plants. Many medicinal plants have pharmacological activities and may, thus, be a source for novel treatment strategies. During the past 10 years, we have systematically analyzed medicinal plants used in traditional Chinese medicine and focused our interest on Artemisia annua L. (qinhuo, sweet wormwood). We found that the active principle of Artemisia annua L., artemisinin, exerts not only antimalarial activity but also profound cytotoxicity against tumor cells. The inhibitory activity of artemisinin and its derivatives towards cancer cells is in the nano- to micromolar range. Candidate genes that may contribute to the sensitivity and resistance of tumor cells to artemisinins were identified by pharmacogenomic and molecular pharmacological approaches. Target validation was performed using cell lines transfected with candidate genes or corresponding knockout cells. The identified genes are from classes with diverse biological functions; for example, regulation of proliferation (BUB3, cyclins, CDC25A), angiogenesis (vascular endothelial growth factor and its receptor, matrix metalloproteinase-9, angiostatin, thrombospondin-1) or apoptosis (BCL-2, BAX, NF-κB). Artesunate triggers apoptosis both by p53-dependent and independent pathways. Antioxidant stress genes (thioredoxin, catalase, γ-glutamylcysteine synthetase, glutathione S-transferases) as well as the epidermal growth factor receptor confer resistance to artemisinic. Cell lines overexpressing genes that confer resistance to established antitumor drugs (MDR1, MRP1, BCRP, dihydrofolate reductase, ribonucleotide reductase) were not cross-resistant to artemunate, indicating that artemisinute is not involved in multidrug resistance. The antitumor activity of some artemisinins has also been shown in human xenograft tumors in mice. First encouraging experience in the clinical treatment of patients suffering from uveal melanoma calls for comprehensive clinical trials with artemisinin for cancer treatment in the near future.

Key words
Angiogenesis · apoptosis · artemisinin · artemisunate · cluster analysis · comparative genomic hybridization · microarrays · oxidative stress · pharmacogenomics

Introduction

Traditional Chinese medicine (TCM)

Medicinal herbs from TCM hold a unique position since an enormous variety of drugs from plant origin is found on more than 5000 years of tradition [1], [2]. Hence, it is assumed that many ineffective prescriptions have disappeared thereby significantly improving the prospect for identifying novel active constituents from TCM [3], [4]. Our interest in natural products from TCM was triggered in the 1990s by sesquiterpene lactones of the artemisinin type from Artemisia annua L. [5]. The Artemisia genus is known to contain many bioactive compounds [6]. Apart from artemisinin, which is in the focus of the present review, we have analyzed cellular and molecular mechanisms of chemically characterized natural products derived from TCM. Among them were known compounds with still insufficiently defined modes of action, which were investigated by us with molecular biological and pharmacogenomic approaches, i.e., arsenic trioxide, ascari...
Botany and geobotany of Artemisia annua L.
This plant belongs to the family of Asteraceae and represents a strong aromatic shrub of 50 - 150 cm in height. The reproduction occurs by insect and self-pollination and wind distribution. The plant represents a typical neophyte in lowlands and hill countries in Asia and Europe with continental to subcontinental climate.

History of artemisinin
The first description of the Chinese herb Artemisia annua L. (sweet wormwood) dates back to the year 168 BC. The plant was mentioned in the prescriptions for 52 diseases in the Mawangdui tomb of the Han dynasty. The next historical tradition is from the year 1086 written by Shen Guo. In the “Handbook of Prescriptions for Emergency Treatment” Ge Hong (281 – 340 B.C.) recommended tea-brewed leaves to treat fever and chills. The “Compendium of Materia Medica” published by Li Shizen in 1596 cited Ge Hong’s prescription. In the course of the Vietnam war, the Chinese government started an antimalarial research program to systematically search for antimalarial TCM plants to support the Vietnamese army. As a result, artemisinin (qinghaosu) was identified in 1972 as the active antimalarial constituent of Artemisia annua L. [18], [19]. Today, artemisinin is widely used worldwide to combat otherwise drug-resistant Plasmodium strains, cerebral malaria, and malaria in children [20]. While Artemisia annua and artemisinin were regarded by the World Health Organization (WHO) with much reluctance for a long time, the full potential was recently recognized.

Besides the use in the treatment of malaria, the bioactivity of artemisinin and its derivatives is much broader. As shown in recent years, its potential application includes the treatment of infections of Schistosoma, Pneumocystis carinii [21], Toxoplasma gondii [22], human cytomegaloviruses, Herpes simplex viruses, and hepatitis B and C [23], [24], [25], [26]. In the 1990s, several groups recognized the cytotoxic activity of artemisinin and its derivatives against tumor cells [27], [28], [29], [30], [31]. The present review focuses on the antimalarial and anticancer activity of artemisinins.

Antimalarial Activity

Antimalarial drug resistance has spread and intensified during the past decades and represents a severe global challenge. It is estimated that 300 – 500 million human beings are infected each year and that 1.5 – 2.5 million individuals die of malaria annually [32], [33]. The development of novel drugs did not parallel this dramatic occurrence of malaria, which even aggravated the problem. Artemisinin and its derivatives are, therefore, promising new drugs on the horizon, which are expected to ease the malaria burden worldwide.

Drug combinations based on artemisinins offer an effective possibility to counteract drug resistance [34]. Combination regimes prolong the useful therapeutic life of existing antimalarial drugs. The probability that a mutant strain of Plasmodium simultaneously exerts resistance to two drugs with different modes of action and different therapeutic targets is low. Combinations of drugs are generally accepted to improve treatment efficacy and to delay the selection of drug-resistant parasites [35]. Indeed, it has been shown that the cure rate of artemunate or artether in combination with mefloquine increased up to 95 – 100% compared to monotherapy with artemisinin derivatives. Other combinations, i.e., artemisinin derivatives and lumefantrine, also improved cure rates [35]. Despite the recommendation of the WHO to use artemisinin-based combination therapies, in order to avoid the emergence of artemisinin resistance, the overall use of such a combination dosage was still unsatisfactory [36]. For this reason, WHO banned artemisinin monotherapy in the year 2006.

Artemisinins proved to be valuable in drug combinations since they are able to reduce the number of parasites by approximately 104 per asexual cycle [37], [38]. Artemisinins are active within 48 – 72 h [39], [40]. This considerably reduces the number of parasites to be killed by a partner drug in a combination regimen. Since they inhibit the production of gametocytes, artemisinins are able to reduce transmission [41].

Another favorable feature of artemisinins is that they are active in the treatment of mild and severe forms of malaria. Severe malaria does not stop with clearing parasitemia. Even if parasites are cleared, the clinical symptoms associated with cerebral malaria may get worse. Besides the brain, other organs such as kidneys or lung can also be injured in severe malaria. Artemisinin has been proven as an effective anti-malarial drug for the treatment of cerebral malaria [42]. Artemisinin derivatives are generally well tolerated [43], [44]. Mild and reversible hematological and electrocardiographic abnormalities, such as neutropenia and first-degree heart block, were observed infrequently. Neurotoxicity, e.g., ataxia, slurred speech and hearing loss, have been reported in a few patients [45]. Due to their lack of severe side effects, artemisinins are also well suited for the treatment of malaria in children [46].

Antitumor Activity of Artemisinin

Multifactorial nature of sensitivity and resistance to anticancer agents
Rather than on the antimalarial activity of artemisinin and its derivatives, our own efforts were focused on the activity of these compounds towards cancer cells. During the past 10 years, we have analyzed molecular mechanisms of artemisinins. We were aware that analysis of the mode of action of a novel compound with activity against tumor cells is compromised by the fact that the response of tumor cells to cytotoxic agents is frequently determined by multiple factors and single mechanisms are not sufficient to account for a drug’s activity [47], [48], [49], [50], [51], [52]. Although anticancer drugs are extremely divergent in their chemical and physical structures and biological actions, a synopsis of the relevant mechanisms influencing drug effects allows their categorization into (i) those acting upstream of the ac-
tual drug target, (ii) those acting at critical target sites or (iii) those acting downstream of them [53], [54].

Mechanisms acting upstream include transporter proteins for uptake or excretion (i.e., ATP-binding cassette transporters, reduced folate carriers, and nucleoside transporters) and drug-metabolizing enzymes that activate, inactivate, or detoxify drugs (i.e., phase I/II enzymes). Metabolizing enzymes and transporter molecules often do not exhibit specificity for certain anticancer drugs but are operative towards a wide array of different xeno

Drug target sites for alkylating agents and platinum drugs are DNA (and DNA repair mechanisms), RNA (RNA synthesis inhibitors, i.e., actinomycin D) and specific proteins such as DNA topoisomerases I/II (camptothecins, anthracyclines, and epipodophyllotoxins), tubulins (Vinca alkaloids and taxanes) or enzymes of DNA biosynthesis (antimetabolites).

Mechanisms downstream of the actual drug targets and at distinct intracellular locations are operative after injury by drugs has been taken place. The most important downstream mechanisms are the diverse apoptosis pathways. Their deregulation may lead to drug resistance and survival of cancer cells despite target molecules have been successfully targeted by anticancer drugs [55], [56]. Programmed cell death is not only regulated by the proteins directly involved in the apoptotic cascade but also by external factors, i.e., by chemokines that act as “survival factors” involved in prevention of apoptosis and, hence, contributing to survival and drug resistance of tumor cells after chemotherapeutic insult [57], [58].

It is, therefore, reasonable to propose that the same is true for cytotoxic compounds from traditional Chinese medicine such as artemisinin and its derivatives (Fig. 1). Since we did not know the relevant upstream, target site, and downstream mechanisms of this class of drugs at the beginning of our studies, we applied pharmacogenomic approaches [59], [60], [61], [62].

**Upstream mechanisms – multidrug resistance**

Importantly, artemisinin and its derivatives are used to treat otherwise drug-resistant *Plasmodia* strains due to their lack of cross-resistance to these class of drugs [63]. Therefore, we addressed the question whether artemisinins are involved in the multidrug-resistance phenotype in tumor cells. Correlating the microarray-based mRNA expression of the multidrug resistance-conferring *ABCB1* gene (*MDR1*: P-glycoprotein) with the IC50 values for artemisinin and seven derivatives did not show significant relationships. Similarly, the flow cytometric measurement of the fluorescent probe rhodamine 123, which represents a functional assay for P-glycoprotein, did not reveal significant correlations to artemisinins [62]. To validate these results obtained by correlation analyses, we used cell lines overexpressing *MDR1/P*-glycoprotein and other drug resistance-conferring genes. We observed that artesunate was similarly active towards drug-sensitive and multidrug-resistant cell lines [60], [64], [65], which overexpress *MDR1/P*-glycoprotein (CEM/ADR5000; CEM/ VCR1000, CEM/VBL100), *MRP1* (CEM/E1000, HL60/AR) or *BCRP* (MDA-MB-231-BCRP). Likewise, methotrexate-resistant CEM/MTX1500LV cells with an amplification of the dihydrofolate reductase (DHFR) gene and hydroxurea-resistant CEM/HUR90 cells with overexpression of ribonucleotide reductase (RRP-M2) were not cross-resistant to artesunate. Artesunate modulated the uptake of doxorubicin in MRPI-overexpressing CEM/E1000 cells, but not in P-glycoprotein-overexpressing CEM/VCR1000 cells [65].

**Upstream mechanisms – oxidative stress response**

In *Plasmodia*, the cleavage of the endoperoxide moiety of artemisin

Fig. 1 Synopsis of mechanisms and candidate genes affecting the response of tumor cells to artesunate.
Focusing on the anticancer activity of artemisinin and its derivatives, we compared the baseline antioxidant mRNA gene expression in the NCI cell line panel with the IC₅₀ values for artemesate [78], [79], [80]. Our results are in favor of oxidative stress as a mechanism of action of artemesate against cancer cells. We found that thioredoxin reductase and catalase expression correlated significantly with the IC₅₀ values for artemesate. WEHI7.2 mouse thymoma cells selected for resistance to hydrogen peroxide or transfected with thioredoxin, manganese superoxide dismutase or catalase showed resistance to artemesate as compared to the parental cell line. The microarray-based mRNA expression of dihydrodiol dehydrogenase, γ-glutamylcysteine synthase (γ-GCS; GLCLR), glutathione S-transferases GSTM4, GSTT2, GSTZ1 and microsomal glutathione S-transferase MGST3 correlated significantly with resistance to artemesate in the NCI cell line panel. A tendency for correlation (0.05 < p < 0.1) was observed for GSTA1, GSTA2, GSTP1 and MGST1. MCF-7 cells transfected with cDNAs for heavy and light subunits of γ-GCS were more resistant to artemesate than mock transfected MCF-7 cells [60]. L-Buthionine sulfoximine, a γ-GCS inhibitor that depletes cellular glutathione pools completely, reversed artemesate resistance in MCF-7 cells [80].

As tumor cells contain much less iron than erythrocytes, but more than other normal tissues [81], the question arises as to whether iron may be critical for artemisinin’s action towards tumor cells. Cellular iron uptake and internalization are mediated by binding of the transferrin-iron complexes to the transferrin receptor (CD71) expressed on the cell surface membrane and by subsequent endocytosis. While most normal tissues are CD71-negative, CD71 is highly expressed in clinical tumors and is widely distributed among clinical tumors [82], [83]. We found that CD71 expression was much higher in CCRF-CEM and U373 tumor cells (48 – 95%) than in peripheral mononuclear blood cells of healthy donors (< 2%) [84]. Iron(II) glycine sulfate (FerroSANOL®) and transferrin increased the cytotoxicity of free artemesate, artemesate microencapsulated in maltosyl-β-cyclodextrin and artemisinin towards CCRF-CEM leukemia and U373 astrocytoma cells if compared with artemisinins applied without iron [84]. This effect was reversed by the monoclonal antibody RV510 against the transferrin receptor, which competes with transferrin for binding to the receptor. The IC₅₀ values for eight different artemisinin derivatives in the NCI cell lines were correlated with the microarray mRNA expression of 12 genes involved in iron uptake and metabolism. The mRNA expression of mitochondrial aconitate and ceruloplasmin (ferrooxidase) correlated significantly with the IC₅₀ values for artemisinins. Interestingly, exposure of artemisinin and its derivatives produces no or only marginal cytotoxicity to non-tumor cells. These results are in accordance with data from other authors [85], [86], [87]. We found that the growth of primary human fibroblasts is almost unaffected by artemesate concentrations up to 100 μM [23]. This implies that tumors that express more CD71 than normal cells might be more affected by combination treatments of transferrin or FerroSANOL® plus artemisinin derivatives. The finding that iron(II) glycine sulfate increased the action of artemisinins is interesting since FerroSANOL® has been in clinical use for many years. Hence, artemisinins might be safely applied in combination with FerroSANOL® in a clinical setting.

**Target site interactions – protein alkylation**

As stated above, artemisinins alkylate specific proteins in the *Plasmodium* parasites, i.e., heme, translationally controlled tumor protein (TCTP) and sarco/endoplasmic reticulum Ca²⁺ ATPases (SERCA) [73], [74], [75], [76], [88]. Whereas SERCA of *Plasmodia* may be affected by artemisinin, it does probably not alkylate human SERCA [76]. We have addressed the question whether TCTP may also be important for artemesate’s action in tumor cells. Interestingly, the microarray-based mRNA expression of TCTP correlated inversely with the IC₅₀ values for artemesate in the NCI tumour cell line panel. Tumor cell lines with high TCTP expression were sensitive to artemesate while low TCTP expression was associated with resistance to artemesate. Although a functional role of TCTP for the activity of artemisinins against tumor cells has not been shown, these results suggest such a role. TCTP represents a proliferation-related Ca²⁺-binding protein, which associates transiently with microtubules during the cell cycle [89]. It has also been implicated in malignant transformation and apoptosis [90], [91].

Despite these results, it should also be considered that artemisinin and its derivatives might alkylate many protein species. It is, therefore, possible that a more unspecified broad-spectrum alkylation of proteins in tumor cells other than the specific alkylation of target proteins account for the growth-inhibitory effects of artemisinins.

Furthermore, the question arises whether artemisinins may alkylate other nucleophilic molecules in the cell such as DNA. It has been reported that artemisinin does not alkylate the DNA of malaria parasites [88]. In own experiments, we did not find that artemesate damages DNA of tumor cells at concentrations able to inhibit tumor cell growth (unpublished data).

**Target site interactions – angiogenesis**

The outgrowth of new blood vessels from pre-existing ones is crucial for tumors to gain access to sufficient amounts of oxygen and nutrients [92]. If tumors reach a size for which diffusion alone cannot supply enough oxygen and nutrients, a process termed angiogenesis is promoted by numerous pro-angiogenic or anti-angiogenic factors. As a consequence, inhibitors of angiogenesis were considered as interesting for cancer treatment [93], [94]. Artemisinin and its derivatives inhibit angiogenesis as shown by several groups including our own [95], [96], [97], [98], [99].

We showed that the microarray-based mRNA expression of 30 out of 90 angiogenesis-related genes correlated significantly with the cellular response to artemisinins [100]. Among this panel were many fundamental angiogenic regulators such as vascular endothelial growth factor C (VEGFC), fibroblast growth factor-2 (FGF1), matrix metalloproteinase 9 (MMP9), thrombospondin-1 (*THBS1*), hypoxia-inducing factor-α (*HIF1A*), angiogenin (*ANG*) and others. By means of hierarchical cluster analysis and cluster image mapping, we identified an expression profile that significantly determined the cellular resistance to several artemisinin derivatives, including artemesate, arteether, artetherm and dihydroartemisinin ester stereoisomer 1. Using Matrigel plugs injected subcutaneously into syngenic mice, we found that artesunate indeed strongly reduced angiogenesis *in vivo*. 
Inhibition of tumor angiogenesis represents, therefore, an important determinant of the anti-tumor effects of artemisinin and its derivatives.

**Downstream mechanisms – apoptosis**

In cluster analyses of microarray experiments, we found that the programmed cell death genes 2, 4, 8, and 9 (PCD2, PCD4, PDCDB, PDCDB9), BCL2-associated athanogenes 1 and 3 (BAG1, BAG3), death-associated protein 6 (DAXX), MAP-kinase activating death domain (MADD), cell death–inducing DFFA-like effector β (CIDEB) and others are possible determinants of the tumor response to artesunate [60]. Since apoptosis is a common mechanism of cell death for most anti-cancer drugs, this may also apply for artemisinin and its derivatives. Indeed, artesunate induces apoptosis as first shown by us and subsequently by others [5], [101], [102], [103], [104], [105]. We identified several apoptosis-regulating genes whose mRNA expression correlated significantly with the IC50 values for artesunate in the NCI cell lines [62]. WEHI7.2 cells transfected with the anti-apoptotic BCL2-gene were more resistant to artesunate than mock-vector-transfected control cells [79], indicating that artesunate may induce apoptosis via the intrinsic mitochondrial pathway of cell death. Furthermore, we found that artesunate acts via p53-dependent and -independent pathways in isogenic p53+/+ p21WAF1/CIP1+/+, p53−/− p21WAF1/CIP1+/+ and p53+/? p21WAF1/CIP1−/− colon carcinoma cells [60]. This was confirmed in a subsequent study with p53 wild-type TK6 and p53 mutated WT1K1 lymphoblastic cells. In both cell lines, we observed a similar sensitivity towards artesunate [84].

**Downstream mechanisms – oncogenes and tumor suppressor genes**

Oncogenes and tumor suppressor genes frequently affect downstream processes in tumor cells, i.e., regulation of apoptosis, differentiation, proliferation etc. Therefore, we categorized the interrelationships between artemisinins and oncogenes/tumor suppressor genes as downstream mechanisms for systematic reasons in this review. The expression of several oncogenes and tumor suppressor genes correlated with the response to artesunate, including expression of epidermal growth factor receptor (EGFR), of the tumor growth factor β (TGFβ), of FBJ murine osteosarcoma viral oncogene homologue B (FOSB), of FOS-like antigen 2 (FOSL2), of the multiple endocrine neoplasia 1 gene (MEN1), of v-myc avian myeloblastosis viral oncogene homologue (MYB), of v-myb avian myelocytomatosis viral oncogene homologue (MYC), of c-src tyrosine kinase (CSK), of v-raf murine sarcoma viral oncogene homologue B1 (BRAF), of the RAS oncogene family members ARHC, ARHE, RAB2 and RAN, of the breast cancer susceptibility gene 2 (BRCA2) and of others [60].

EGFR represents an exquisite target for therapeutic interventions. It contributes to the development of drug resistance, and EGFR-coupled signal transduction pathways activate mitogenic and other cancer-promoting processes, e.g., proliferation, angiogenesis, and inhibition of apoptosis [106]. For this reason, we analyzed it in more detail. In agreement with the microarray data, we found that glioblastoma cells transfected with a deletion-activated EGFR cDNA were more resistant to artesunate than the control cells [60].

Furthermore, we found synergistic effects for the combination treatment with the EGFR tyrosine kinase inhibitor erlotinib (Tarceva, OSI-774) and artesunate in glioblastoma cells transfected with a deletion-activated EGFR cDNA and we found additive effects in wild-type EGFR transfectants [107]. We determined a profile of chromosomal gains and losses by comparative genomic hybridization in nine non-transfected glioblastoma cell lines. The correlation of the genomic aberrations in these cell lines with the IC50 values for the combination treatment of artesunate and erlotinib pointed to certain genomic loci. The identified genes may serve as candidate genes for determining sensitivity and resistance. Currently, they are under further investigation.

**Preclinical and preliminary clinical studies**

The activity of artemisinin and its derivatives in vivo has been shown by several authors. Moore et al. [85] found that the growth of fibrosarcoma in Fisher 344 rats was significantly delayed by the daily application of the active metabolite of artemisinin, dihydroartemisinin, plus ferrous sulfate if compared to untreated control animals. Chen et al. [108] used the chorioallantoic membrane (CAM) assay in chicken eggs. It is widely accepted for analysis of the development of blood vessels in vivo. The CAM assay is particularly suited for the screening of angiogenesis inhibitors. Dihydroartemisinin significantly suppressed neoangiogenesis in this test system. These results correlate with results of our own investigations [98]. We soaked Matrigel plugs with vascular epithelial growth factor (VEGF), tumor necrosis factor-α (TNF-α) and heparin, which act as strong stimuli for angiogenesis. The Matrigel plugs were subcutaneously injected into nude mice. In control animals without artesunate treatment, a strong vascularization-based filling of the plugs with blood took place after four days. In contrast, a statistically significant reduction in Matrigel vascularization was observed in mice fed with artesunate in the drinking water. To determine the in vivo effects of artesunate on tumor growth, we subcutaneously injected KS-IMM Kaposi sarcoma cells to nude mice [98]. Whereas strong tumor growth was found in untreated mice, it was strongly suppressed in artesunate-treated animals. These results were subsequently confirmed by other authors. Disbrow et al. [109] found that dihydroartemisinin inhibited virus-induced tumor formation in vivo. Dogs infected with canine oral papillomavirus developed tumors in the oral mucosa. The tumor development was, however, significantly inhibited by topical application of dihydroartemisinin. Lai and Singh [110] induced breast cancer in rats by application of 7,12-dimethylbenz[a]anthracene (DMBA). In comparison to untreated control animals, rats fed with artemisinin showed delayed tumor development and decreased tumor size. Furthermore, fewer rats showed multiple breast tumors, and the occurrence of tumors was generally lowered.

The successful treatment of human xenograft tumors in nude mice with artesunate [98] encouraged us to apply artesunate in a clinical setting. We have treated two patients suffering from uveal melanoma on a compassionate-use basis after standard chemotherapy alone was ineffective in stopping tumor growth [111]. Generally, such tumor patients have a median survival time of 2–5 months. Upon use of artesunate, no additional side effects exceeding those caused by standard chemotherapy were observed indicating that artesunate was well tolerated. One pa-
tient experienced a temporary response after the addition of ar-
tesunate while the disease was progressing under standard ther-
apy with fotemustine alone. The patient died after 24 months.
The second patient first experienced a stabilization of the disease
following use of artesunate plus iron in combination with the
standard drug dacarbazine followed by objective regressions of
splenic and lung metastases. This patient is still alive 47 months
after first diagnosis of stage IV uveal melanoma. This promising
result indicates that artesunate might be a valuable adjuvant
drug for the treatment of melanoma and other tumors in com-
mination with standard chemotherapy. The treatment of a pituitary
macroadenoma with artemether has been reported recently
[112]. Comprehensive clinical trials are needed to establish the
efficacy of artesunate in cancer therapy.

Mechanistic Basis for Common Modes of Action
of Artemisinin in Plasmodium and Cancer

Reactive oxygen species, radical molecules and iron
After absorption, artemisinin derivatives such as artesunate are
metabolized in the liver by phase II enzymes (cytochrome P450
monoxygenases) to dihydroxyartemisinin, which retains its
bioactivity. Artemisinin itself is not converted to dihydroxyarte-
minisin [113], [114].

In malaria parasites, artemisinin acts by a two-step mechanism.
It is first activated by intraparastic heme-iron, which catalyzes
the cleavage of the endoperoxide. The Plasmodium trophozoites
and schizonts live within red blood cells. Here, they take up and
digest hemoglobin. The heme-derived iron facilitates the clea-
avage of artemisinin’s endoperoxide moiety by a Fe(II) Fenton re-
action. This results in the generation of reactive oxygen species
and carbon-centered radical species [68], [69], [70], [71], [72].
Cleavage of the endoperoxide bond of artemisinin and its deriva-
tives leads to the alklylation of heme and some Plasmodium-
specific proteins, including the P. falciparum translationally con-
trolled tumor protein (TCTP), histidine-rich protein (42 kDa) and
PfATP6, the sarco-/endoplasmic reticulum Ca²⁺ ATPase (SERCA)
orthologue of P. falciparum [73], [74], [75]. Binding of artemisinin
to the parasite’s DNA has not been observed [115].

As the iron storage in tumor cells is generally decreased compar-
ed to that of erythrocytes but increased in tumor cells if compar-
ed to normal cells [81], the question arises as to whether iron
may also play a role in the inhibitory action of artesminins to-
wards tumor cells [116]. The growth rate of a tumor was signifi-
cantly slowed down by daily oral administration of ferrous sul-
fate followed by dihydroartemisinin. No significant tumor
growth retardation effect was observed in rats treated with ei-
ther dihydroartemisinin or ferrous sulfate alone. Drug treatment
did not significantly affect body weight if compared with un-
treated tumor-implanted animals, and no apparent toxic effect
was observed after drug treatment [85]. Iron(II) glycine sulfate
(Ferroسانول®) and transferrin increased the cytotoxicity of free
artesunate, artesunate microencapsulated in maltosyl-β-cyclo-
dextrin and artemisinin towards CCRF-CEM leukemia and U373
astrocytoma cells if compared with that of artemisinin applied
without iron [84]. Growth inhibition by artesunate and ferrous
iron correlated with induction of apoptosis. The effect of ferrous
iron and transferrin was reversed by the monoclonal antibody
RVS10 against the transferrin receptor, which competes with
transferrin for binding to the receptor. The IC₅₀ values for eight
different artemisinin derivatives in the NCI cell line panel were
correlated with the microarray mRNAexpression of 12 genes in-
volved in iron uptake and metabolism in order to identify iron-
responsive cellular factors enhancing the activity of artesimi-
nins. This analysis pointed to mitochondrial aconitase and ceru-
loplasmin (ferrooxidase). Interestingly, exposure of artemisinin
and its derivatives produces no or only marginal cytotoxicity to
normal peripheral blood mononuclear cells (PBMC).

Role of the transcription factor NF-κB
Artemisinin-type compounds belong to the class of sesquiter-
penes. This is a group of natural products present in medicinal
plants all over the world with well-known anti-inflammatory ac-
tivities. Several investigations showed that the anti-inflamma-
tory activity is at least in part due to inhibition of the nuclear
transcription factor κB (NF-κB) [117], [118], [119]. Molecular
docking studies using the three-dimensional crystal structure of
NF-κB revealed that many sesquiterpene lactones attack the cy-
steine-38 residue of the p54/NF-κB subunit [120], [121], [122],
[123].

In 2002, we were the first to demonstrate that artesunate inhib-
its NF-κB activity, leading to the inhibition of viral replication.
NF-κB is involved in the transcriptional regulation of immediate
early, early and late proteins of human cytomegalovirus (HCMV)
necessary for viral replication [23]. Subsequent studies also sup-
port a role of artemisinin-type compounds in NF-κB inhibition.
Aldieri et al. [124] found that artemisinin inhibits NF-κB activity
and thereby blocks nitric oxide synthesis. Dihydroartemannin, a
semisynthetic derivative of artemisinin, is also able to inhibit
NF-κB [125]. Tripathi et al. [126] reported increased expression
levels of the adhesion molecule ICAM-1 (intercellular cell adhe-
sion molecule-1) in human brain microvascular endothelial cells
(HBMEC) after exposure to artemisinin. ICAM-1 is involved in se-
questration of Plasmodium falciparum-infected erythrocytes in the
postcapillary brain endothelium. This represents a typical
feature of cerebral malaria pathogenesis. Artemisinin reduced
ICAM-1 expression in endothelial cells. As ICAM-1 expression
is regulated by NF-κB, it is reasonable that artemisinin improves
the therapeutic efficacy in cerebral complications during malaria
infections. These results suggest that there is a common me-
chanistic basis for explaining the effects of artemisinin and its
derivatives against malaria infections, viral infections and tumor
cells.

Biotechnological Approaches for the Production of
Artemisinin

The yield of artemisinin in wild populations of Artemisia annua is
low (0.01–0.8%). Therefore, there is a considerable limitation to
commercialization of the drug [127], [128]. Total synthesis of the
product is feasible but time-consuming and expensive. Several
synthesis routes with (+)-isopulegol, (+)-isolimenene or (R)-(−)-
pulegone as starting molecules have been described [129], [130],
[131] (Fig. 2). The semi-synthetic production of artemisinin from
its precursor artemisinic acid has also been shown. Artemisinic
acid is present in 10-fold excess in the plants. Hence, the semi-
synthetic artemisinin yield is considerably higher than the iso-
lolation of artemisinin from plants. To preserve the natural resources
of *Artemisia annua* plants, artemisinin-like endoperoxides, e.g.,
arteflene, have been synthesized chemically [132].

Other possibilities for meeting the high demand for artemisinin
are found in the natural production of artemisinin by phytother-
aputical and agricultural approaches and in biotechnological
approaches.

Phytotherapeutical and agricultural approaches [133], [134] allow:
- The cultivation of wild-type plants in fields and greenhouses.
- The breeding of high-yield cultivars. The artemisinin contents
vary between individual plants even under comparable culti-
vation conditions (temperature, humidity, characteristics of
the soil, etc.). Classical breeding techniques allow to cross
high yield clones and to create synthetic variants of *Artemisia
annua*.
- The cultivation of transgenic plants. Genetically modified
plants deliver considerably higher amounts of artemisinin
than wild-type plants.

In Africa, *Artemisia annua* plants are used in herbal teas to treat
malaria. This has been critically discussed in terms of increased
probability of resistance development against artemisinin [135].
The professional cultivation in fields and greenhouses allows the
isolation artemisinin for further pharmaceutical processing.

Biotechnological approaches provide attractive possibilities for
the large-scale production of artemisinin:
- Hairy root cultures of *Artemisia annua* can be generated by in-
fection of roots with *Agrobacterium rhizogenes*. Hairy roots
grow quickly, reach high densities and can produce significant
amounts of secondary metabolites such as artemisinin [136],
[137].
- The production of artemisinin in cell cultures in vitro [138].
- The expression of the biosynthetic pathway for artemisinin or
related metabolites in genetically modified organisms, i.e.
*E.coli* and *Aspergillus flavipes* [139], [140], [141] or
*Saccharomyces cerevisiae* [142] has been reported. It is a pre-
requisite that the biosynthetic pathways for artemisinins in
*Artemisia annua* are known. The biosynthesis of artemisinin
has been elucidated, and the corresponding genes have been
cloned. In brief, starting from the cytosolic MVA pathway
(3R-mevalonic acid) and 3-acetyl-CoA on one side and from
the plastidial DXP pathway (1-deoxy-d-xylulose 5-phosphate),
pyruvate and glyceraldehyde 3-phosphate as starting
molecules on the other side, several enzymatic steps lead to
the synthesis of farnesyl diphosphate. Several further enzy-
matic reactions result in the generation of dihydroartemisinic
acid and artemisinin (Fig. 3) (for a detailed representation of
the biosynthesis of artemisinin, see reviews [143], [144]. If
coding genes of these enzymes are transferred to microorgan-
isms such as bacteria or yeast, it should be possible to recon-
struct the biosynthetic pathway of artemisinin in these organ-
isms.
Biotechnological approaches for the large-scale production of artemisinin represent a technical challenge. The obtainable yields should exceed the ones obtained by classical breeding methods. The artemisinin yield of one ton dry leaves of wild-type *Artemisia annua* is 6 kg per hectare. Time to grow is 100 – 120 days allowing three harvests per year under optimal conditions 18 kg artemisinin/hectare and year. With the use of genetically engineered organisms, it should be possible to produce 25 kg artemisinin within an 8-hours working day. This calculation is based on the assumption that engineered yeast will produce 100 – 150 mg artemisinin per liter culture medium or 100 – 150 g/1000 liter in an industrial set-up. The doubling time of yeast is about 1 h; hence, starting with 100 g artemisinin at time point 0 will result in 25.6 kg artemisinin after 8 h.

With the implementation of sophisticated biotechnological production techniques, it will be possible to meet the high demand for artemisinin for malaria treatment and hopefully in the future for cancer chemotherapy as well.

**References**


125 Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroartemisinin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappaB translocation. Int Immunopharmacol 2006; 6: 1243–50.


